TD-1607 SAD Study in Healthy Subjects

NCT01791049 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Serious Infections Due to Known or Suspected Gram-positive Pathogens

Interventions

DRUG: TD-1607
DRUG: Placebo

Sponsor

Theravance Biopharma